Pre-Conference Workshop Day

Tuesday September 21, 2021 | 8am - 6pm EST

Workshop A: Immune Response Mitigation Strategies for the Eye | 8am - 11am

With the eye being an immune privileged site lends ophthalmic disorders make a an optimal target for gene therapy vectors, often associated with toxic effects. However, there are still off target effects and inflammation as a result of delivery route.

Workshop will  include:

  • Understanding the biology of immune reactions of the eye
  • Discussing inflammation and its impact on trials
  • Pros & cons of subretinal delivery such as scalability
  • Evaluating different strategies being used in the clinic to manage side effects
Dominic Fishcer

Dominik Fischer
Principal Investigator &
Consultant Ophthalmic Surgeon
Oxford Eye Hospital

Workshop B: Translating Next Generation Vectors for the Eye | 11:30am - 2:30pm

To overcome delivery challenges, novel vectors are designed to improve specificity, mitigate off target effects and enhance efficacy.

Workshop will include:

  • Discovery and preclinical data for novel vectors targeting the retina
  • Exploring novel preclinical models of ophthalmic disorders and optimizing the data obtained
  • Discussing current early clinical data for novel vectors
Sanford Boye

Sanford Boye
Director of Vector Core,
Powell Gene Therapy Center
University of Florida

Chief Technology Officer
Atsena Therapeutics

Workshop C: Antisense Oligonucleotides: Evaluating Different Approaches for Ophthalmic Disorders | 11:30am - 2:30pm

Evaluating the progress with antisense oligonucleotides, cell therapy and alternative therapies for the treatment of retinal disorders to improve your understanding of the wider ophthalmology landscape.

Aniz_AH

Aniz Girach
Chief Medical Officer
ProQR

Workshop D: Showcasing the Translatability of Suprachoroidal Delivery | 3pm - 6pm

With scalability challenges, the invasive nature and specialised skill set required for subretinal delivery, intravitreal delivery optimization is a priority for the field. Providing an alternative outpatient approach however is suprachoroidal delivery, which is showing promise in preclinical research.

Workshop will include:
• An explanation of suprachoroidal delivery and its advantages
• Recent preclinical and clinical data to support its implementation into gene therapy programs

thomas c

Thomas Ciulla
Vitreoretinal Medicine & Surgery, Chief
Medical Officer & Chief Development Officer
Clearside Biomedical Inc.

peter c

Peter Campochiaro
Director, Retinal Cell & Molecular
Laboratory; Professor of Ophthalmology
Johns Hopkins
University School of Medicine